Jan 6, 2026 10:31AM Raymond James on Taysha Gene Therapies (TSHA): 'Continued Regulatory Progress For TSHA-102; Remain Strong Buy Rated'

Jan 6, 2026 08:02AM Taysha Gene Therapies doses first patient in Rett syndrome pivotal trial

Dec 17, 2025 05:28AM Taysha's (TSHA) 'Moving into Registrational Studies, Shows Promise' - Citizens

Dec 4, 2025 05:08AM Goldman Sachs Upgrades Taysha Gene Therapies (TSHA) to Buy

Nov 14, 2025 07:26AM Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA)

Nov 5, 2025 05:11AM Taysha Gene Therapies (TSHA) PT Raised to $8 at Citizens on Competitive Advantage

Nov 4, 2025 08:33AM Taysha Gene Therapies (TSHA) files mixed shelf

Nov 4, 2025 07:04AM Taysha Gene Therapies (TSHA) Reports In-Line Q3 EPS

Oct 20, 2025 04:10PM Raymond James Starts Taysha Gene Therapies (TSHA) at Strong Buy

Oct 17, 2025 07:15AM Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA): Says it's Undervalued

Oct 16, 2025 04:02PM Taysha Gene Therapies regains full rights to TSHA-102 Rett syndrome program

Oct 13, 2025 04:41AM Citizens Reiterates Market Outperform on Taysha Gene Therapies (TSHA), Sees Edge in Rett Therapy

Oct 2, 2025 01:04PM Taysha Gene Therapies (TSHA) PT Raised to $12 at Baird

Sep 22, 2025 07:19AM Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA)

Sep 12, 2025 04:11AM Citizens JMP Reiterates Market Outperform Rating on Taysha Gene Therapies (TSHA)

Aug 13, 2025 06:23AM Taysha Gene Therapies (TSHA) PT Raised to $14 at Canaccord Genuity

Aug 12, 2025 08:04AM Taysha Gene Therapies (TSHA) Misses Q2 EPS by 1c

Jul 11, 2025 06:37AM BofA Securities Starts Taysha Gene Therapies (TSHA) at Buy

Jun 13, 2025 07:11AM Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA)

Jun 12, 2025 07:24AM Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA)

Jun 3, 2025 05:26PM Taysha Gene Therapies (TSHA) announces presentations for TSHA-102 program

Jun 3, 2025 06:59AM Taysha Gene Therapies (TSHA) PT Raised to $11 at Canaccord Genuity

May 29, 2025 08:01AM Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA)

May 29, 2025 04:12AM Taysha Gene Therapies (TSHA) PT Raised to $6 at Citizens JMP

May 28, 2025 04:02PM Taysha Gene Therapies (TSHA) Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

May 28, 2025 04:01PM Taysha Gene Therapies (TSHA) Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult

May 15, 2025 03:33PM Baird Reiterates Outperform Rating on Taysha Gene Therapies (TSHA); 'Encouraged by FDA Interactions'

May 15, 2025 08:02AM Taysha Gene Therapies (TSHA) Tops Q1 EPS by 1c

Apr 28, 2025 07:17AM Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA)

Apr 28, 2025 05:37AM Citizens JMP Reiterates Market Outperform Rating on Taysha Gene Therapies (TSHA)

Mar 31, 2025 07:25AM Truist: 'Expect Some Pressure On Dr. Marks' Resignation'

Jan 6, 2025 02:00PM 7 top biotech picks for 2025 according to Wells Fargo

Nov 15, 2024 07:07AM Taysha Gene Therapies (TSHA) PT Raised to $8 at Canaccord Genuity

Nov 13, 2024 04:03PM Taysha Gene Therapies (TSHA) Misses Q3 EPS by 1c

Nov 12, 2024 07:58AM Piper Sandler Reiterates Overweight Rating on Taysha Gene Therapies (TSHA)

Nov 5, 2024 06:12AM Baird Reiterates Outperform Rating on Taysha Gene Therapies (TSHA)

Aug 14, 2024 10:16AM BMO Capital Reiterates Outperform Rating on Taysha Gene Therapies (TSHA)

Aug 14, 2024 06:33AM Taysha Gene Therapies (TSHA) PT Lowered to $6 at Canaccord Genuity

Aug 12, 2024 08:04AM Taysha Gene Therapies (TSHA) Tops Q2 EPS by 7c

Jul 1, 2024 07:13AM Taysha Gene Therapies (TSHA) PT Lowered to $7 at Piper Sandler

Jun 26, 2024 04:05PM BMO Capital Starts Taysha Gene Therapies (TSHA) at Outperform

Jun 26, 2024 09:15AM Taysha Gene Therapies (TSHA) Prices 14.36M Share and Warrant Offering at $2.25/sh

Jun 26, 2024 02:58AM Taysha Gene Therapies (TSHA) Announces Proposed $75M Share and Warrant Offering

Jun 18, 2024 07:30AM Taysha Gene Therapies (TSHA) Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in REVEAL Phase 1/2 Trials